Low-Dose Naltrexone

About this approach

Low-dose naltrexone refers to using an opioid-blocking medicine in a regimen different from its established use for alcohol or opioid dependence. It is sometimes promoted for pain, inflammatory conditions or immune support, including in cancer programs. These are separate claims with different evidence. Research has not established LDN as a treatment that controls cancer or prolongs survival. Its interaction with opioid pain medicines is particularly important for anyone receiving cancer-related symptom management.

Where it fits: Off-label investigational use; anticancer benefit is unproven

Where this treatment is used

Proposed mechanisms involve opioid receptors and inflammatory signaling, but a plausible mechanism is only an early step in evaluating a treatment. NCI lists naltrexone as a medicine being studied in cancer-related settings; inclusion in a drug dictionary or trial directory is not an effectiveness recommendation. Cancer case reports and combination protocols cannot reliably isolate the contribution of naltrexone. A discussion should distinguish a symptom-focused research question from a claim to suppress tumor growth. Larger, well-designed trials are needed to identify which uses, if any, have a favorable balance of benefit and harm in people with cancer.

Procedure and practical considerations

Naltrexone can block opioid pain relief or trigger withdrawal in someone using opioids. This matters for prescribed pain medicines, some cough or diarrhea products, and medications used to treat opioid dependence. Nausea, headache, sleep disturbance and vivid dreams may occur; liver or kidney problems also require review. Do not adjust pain medicines to accommodate LDN without the prescribing team. Provide a complete medication list and make sure any emergency clinician knows about naltrexone use.

Clinics reporting this approach

These clinic profiles mention this approach in their published materials. Open a profile to compare locations, services, practical details, and ways to get started.